Danaher Corporation $DHR Stock Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC decreased its stake in shares of Danaher Corporation (NYSE:DHR) by 2.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 173,239 shares of the conglomerate’s stock after selling 3,944 shares during the period. Nisa Investment Advisors LLC’s holdings in Danaher were worth $38,450,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of DHR. BlackRock Inc. bought a new position in Danaher during the 2nd quarter valued at $10,492,520,000. Wellington Management Group LLP boosted its holdings in Danaher by 10.4% during the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after acquiring an additional 1,542,310 shares during the last quarter. Jupiter Topco LLC purchased a new position in Danaher during the 2nd quarter worth $1,456,317,000. Generation Investment Management LLP bought a new stake in shares of Danaher in the 2nd quarter worth $1,287,949,000. Finally, Bank of America Corp DE bought a new stake in shares of Danaher in the 2nd quarter worth $993,846,000. Institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

DHR has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $240.00 target price on shares of Danaher in a report on Wednesday, July 22nd. Morgan Stanley upped their price objective on shares of Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Barclays upped their price objective on shares of Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Wall Street Zen lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, UBS Group started coverage on shares of Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus price target of $235.41.

Danaher Trading Up 0.2%

Shares of Danaher stock opened at $224.78 on Wednesday. The firm has a market cap of $158.02 billion, a PE ratio of 39.93, a P/E/G ratio of 2.82 and a beta of 0.76. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The stock has a fifty day moving average price of $214.70 and a 200-day moving average price of $196.54.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.77 EPS. Equities research analysts anticipate that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is 28.42%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.